摘要
目的:探讨白芍总苷联合沙利度胺治疗强直性脊柱炎对患者活动指标及血清炎性因子水平的影响。方法:选取强直性脊柱炎患者60例,按治疗方式分为两组,各30例,对照组仅予以沙利度胺进行治疗,研究组予以沙利度胺联合白芍总苷进行治疗,比较两组治疗效果、活动指标、炎性因子水平变化情况以及出现不良事件的概率。结果:对照组治疗有效率低于研究组(P<0.05),治疗后对照组各指标水平低于研究组(P<0.05),治疗后对照组白介素-17(IL-17)、C反应蛋白(CRP)、白介素-1β(IL-1β)水平都高于研究组(P<0.05),对照组出现不良事件的概率高于研究组(P<0.05)。结论:在治疗强直性脊柱炎患者的过程中,白芍总苷联合沙利度胺治疗效果显著。
Objective:To investigate the effect of total glucosides of paeony combined with thalidomide on activity indicators and serum inflammatory factors in the treatment of ankylosing spondylitis patients. Method:60 cases of ankylosing spondylitis patients were randomly divided into research group and control group,each 30 cases. The control group was treated with thalidomide. The research group was treated with total glucosides of paeony and thalidomide. Treatment effect,activity indicators,inflammatory factor levels and the probability of adverse events were compared. Results:The effective rate of treatment in the control group was lower than that in the research group(P<0.05). After treatment,all indexes in the control group were worse than those in the research group(P<0.05),the levels of IL-17,CRP and IL-1 beta in the control group were higher than those in the research group(P<0.05),and the probability of adverse events in the control group was higher than that in the research group(P<0.05). Conclusion:In the treatment of ankylosing spondylitis patients,treatment effect of total glucosides of paeony combined with thalidomide is significant,which is worthy of more extensive clinical application.
作者
沈斯瑶
刘艳
徐鹏刚
SHEN Siyao;LIU Yan;XU Penggang(Xi’an No.5 Hospital,Xi’an 710082)
出处
《陕西医学杂志》
CAS
2020年第1期20-23,共4页
Shaanxi Medical Journal
基金
陕西省中医管理局中医药科研课题(15-SCJH037)
关键词
白芍总苷
沙利度胺
强直性脊柱炎
活动指标
血清炎性因子水平
不良事件
Total glucosides of paeony
Thalidomide
Ankylosing spondylitis
Activity indicators
Serum inflammatory factor levels
Adverse events
